Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 6/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | STK4 | Q13043 | 1/20 | 0.39 |
| ▸ | STK3 | Q13188 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582205 | 0.89 | CSNK2A2 (0.52) | CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1 | |
| SCHEMBL5582178 | 0.88 | VNN1 (0.45) | VCPCSNK2A1CSNK2A2CSNK2BMAP4K4 | |
| SCHEMBL5582210 | 0.88 | CSNK2A1 (0.51) | CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1 | |
| SCHEMBL5582212 | 0.86 | CSNK2A1 (0.49) | CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1 | |
| SCHEMBL5582245 | 0.84 | CSNK2A1 (0.51) | CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1 | |
| SCHEMBL5582246 | 0.83 | STK4 (0.43) | VCPADORA1STK4STK3 | |
| SCHEMBL5582238 | 0.81 | MAP4K4 (0.52) | CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1 | |
| SCHEMBL5581995 | 0.80 | CSNK2A1 (0.50) | CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1 | |
| SCHEMBL5582194 | 0.80 | CSNK2A1 (0.48) | CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1 | |
| SCHEMBL5581974 | 0.80 | MAP4K4 (0.45) | CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | VCP 4804/4885CSNK2A1 602/4885CSNK2A2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.